Efficacy and safety of combination targeted ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study.
Author(s) :
Guillo, Lucas [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Flachaire, Benoit [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Avouac, Jerôme [Auteur]
Hôpital Cochin [AP-HP]
Dong, Catherine [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bouguen, Guillaume [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]
Buisson, Anthony [Auteur]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Caillo, Ludovic [Auteur]
Hôpital Universitaire Carémeau [Nîmes] [CHU Nîmes]
Fumery, Mathurin [Auteur]
Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV [PERITOX]
Gilletta, Cyrielle [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Hébuterne, Xavier [Auteur]
Université Côte d'Azur [UniCA]
Lafforgue, Pierre [Auteur]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Laharie, David [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Mahé, Emmanuel [Auteur]
Centre Hospitalier Victor Dupouy
Marotte, Hubert [Auteur]
Biologie Intégrative du Tissu Osseux [LBTO]
Nancey, Stéphane [Auteur]
Centre International de Recherche en Infectiologie [CIRI]
Ottaviani, Sébastien [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Salmon, Jean-Hugues [Auteur]
Vieillissement, Fragilité [VIEFRA - EA 3797]
Savoye, Guillaume [Auteur]
Université de Rouen Normandie [UNIROUEN]
Serrero, Mélanie [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Uzzan, Mathieu [Auteur]
Hôpital Beaujon [AP-HP]
Viguier, Manuelle [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Richez, Christophe [Auteur]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Peyrin-Biroulet, Laurent [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Seksik, Philipe [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Pham, Thao [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Assistance Publique - Hôpitaux de Marseille [APHM]
Flachaire, Benoit [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Avouac, Jerôme [Auteur]
Hôpital Cochin [AP-HP]
Dong, Catherine [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Nachury, Maria [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bouguen, Guillaume [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]
Buisson, Anthony [Auteur]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Caillo, Ludovic [Auteur]
Hôpital Universitaire Carémeau [Nîmes] [CHU Nîmes]
Fumery, Mathurin [Auteur]

Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV [PERITOX]
Gilletta, Cyrielle [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Hébuterne, Xavier [Auteur]
Université Côte d'Azur [UniCA]
Lafforgue, Pierre [Auteur]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Laharie, David [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Mahé, Emmanuel [Auteur]
Centre Hospitalier Victor Dupouy
Marotte, Hubert [Auteur]
Biologie Intégrative du Tissu Osseux [LBTO]
Nancey, Stéphane [Auteur]
Centre International de Recherche en Infectiologie [CIRI]
Ottaviani, Sébastien [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Salmon, Jean-Hugues [Auteur]
Vieillissement, Fragilité [VIEFRA - EA 3797]
Savoye, Guillaume [Auteur]
Université de Rouen Normandie [UNIROUEN]
Serrero, Mélanie [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Uzzan, Mathieu [Auteur]
Hôpital Beaujon [AP-HP]
Viguier, Manuelle [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Richez, Christophe [Auteur]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Peyrin-Biroulet, Laurent [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Seksik, Philipe [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Pham, Thao [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Journal title :
Digestive and Liver Disease
Abbreviated title :
Dig Liver Dis
Volume number :
55
Pages :
61-68
Publication date :
2022-08-24
ISSN :
1878-3562
English keyword(s) :
Combination therapy
Molecular targeted therapy
Immune-mediated inflammatory diseases
Molecular targeted therapy
Immune-mediated inflammatory diseases
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background
Use of a combination of targeted therapies (COMBIO) in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs) has increased, but reported data remain scarce. We aimed to assess ...
Show more >Background Use of a combination of targeted therapies (COMBIO) in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs) has increased, but reported data remain scarce. We aimed to assess effectiveness and safety of COMBIO in patients with IMIDs. Methods We conducted a French ambispective multicenter cohort study from September 2020 to May 2021, including adults’ patients with 1 or 2 IMIDs and treated at least 3-month with COMBIO. Results Overall, 143 patients were included. The most common IMIDs were Crohn's disease (63.6%), axial spondyloarthritis (37.7%), and ulcerative colitis (14%). Half of patients had only one IMID, of which 60% were Crohn's disease. Mean duration of COMBIO was 274.5±59.3 weeks, and COMBIO persistence at 104 weeks was estimated at 64.1%. The most frequent COMBIOs combined anti-TNF agents with vedolizumab (30%) or ustekinumab (28.7%). Overall, 50% of patients achieved significant and 27% mild-to-moderate improvement in patient-reported outcomes. Extended duration of COMBIO (aOR=1.09; 95% CI: 1.03-1.14; p=0.002) and diagnoses of two IMIDs (aOR=3.46; 95%CI: 1.29-9.26; p=0.013) were associated with significant improvement in patient-reported outcomes. Incidence of serious infection during COMBIO was 4.51 per 100 person-years (95% CI 2.20-8.27) and 5 COMBIOs were discontinued due to adverse events. Conclusions COMBIO can be effective and safe in patients with refractory/overlapping IMIDs.Show less >
Show more >Background Use of a combination of targeted therapies (COMBIO) in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs) has increased, but reported data remain scarce. We aimed to assess effectiveness and safety of COMBIO in patients with IMIDs. Methods We conducted a French ambispective multicenter cohort study from September 2020 to May 2021, including adults’ patients with 1 or 2 IMIDs and treated at least 3-month with COMBIO. Results Overall, 143 patients were included. The most common IMIDs were Crohn's disease (63.6%), axial spondyloarthritis (37.7%), and ulcerative colitis (14%). Half of patients had only one IMID, of which 60% were Crohn's disease. Mean duration of COMBIO was 274.5±59.3 weeks, and COMBIO persistence at 104 weeks was estimated at 64.1%. The most frequent COMBIOs combined anti-TNF agents with vedolizumab (30%) or ustekinumab (28.7%). Overall, 50% of patients achieved significant and 27% mild-to-moderate improvement in patient-reported outcomes. Extended duration of COMBIO (aOR=1.09; 95% CI: 1.03-1.14; p=0.002) and diagnoses of two IMIDs (aOR=3.46; 95%CI: 1.29-9.26; p=0.013) were associated with significant improvement in patient-reported outcomes. Incidence of serious infection during COMBIO was 4.51 per 100 person-years (95% CI 2.20-8.27) and 5 COMBIOs were discontinued due to adverse events. Conclusions COMBIO can be effective and safe in patients with refractory/overlapping IMIDs.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Submission date :
2024-01-12T00:49:46Z
2024-02-27T14:28:14Z
2024-02-27T14:28:14Z